



Est. by the Hepatitis B Foundation

The *Pennsylvania Biotechnology Center of Bucks County* is a nonprofit corporation, created as a place of discovery, education and job creation, and is an innovative space for entrepreneurs and biotech startups. Our mission is to help expand research capabilities and support efforts to accelerate the pace of research.

Member organizations resident at the Pennsylvania Biotechnology Center currently fall into the following categories:

- Non-Profit Research & Development
- Non-Profit Outreach and Education
- Biotechnology
- Medicinal Chemistry Technologies
- Contract Research Organizations (CROs)
- Medical Device Technologies
- Nanotechnology
- Facilities Support
- Biotechnology Business Services

NONPROFIT RESEARCH & DEVELOPMENT

Baruch S. Blumberg Institute	
<p>Research & Development on Hepatitis, diseases of the liver, and other infectious diseases</p> <p>CEO: Tim Block, Ph.D. tim.block@bblumberg.org 215-589-6300 Blumberginstitute.org</p>	<p>The mission of the Baruch S. Blumberg Institute is to use discovery science to find new therapies for viral hepatitis and liver cancer; to advance its research discoveries through traditional scholarship and educational opportunities; to nurture biotechnology entrepreneurship; and to promote public health outreach programs to improve the quality of life for those affected by viral hepatitis.</p>
Pennsylvania Drug Discovery Institute	
<p>Engaging with the future</p> <p>Dr. Dennis M. Gross, CEO Dr. Allen Reitz, President padrugdiscovery.org dgross@padrugdiscovery.org 267-893-6777</p>	<p>The Pennsylvania Drug Discovery Institute (PDDI) is a non-profit outreach and technology transfer organization that seeks to promote the translation of basic discoveries in biomedical research into commercial opportunities. The PDDI hosts scientific and business development seminars in the life sciences, hosts an Annual Award and Lecture in the fall, and maintains a collection of >30,000 reagents and starting materials for use by life science entrepreneurs and academic and non-profit research organizations. In addition, the PDDI is involved with both undergraduate and graduate education programs at local universities and engages with regional STEM activities in an advisory role.</p>

NONPROFIT (Outreach and Education)

Geisinger Commonwealth School of Medicine

geisinger.edu/education

Geisinger Commonwealth School of Medicine (Geisinger Commonwealth) offers a community-based model of undergraduate medical education with campuses in Scranton, Danville, Sayre and Wilkes-Barre. The school's innovative Doctor of Medicine (MD) degree curriculum, focused on caring for people in the context of their lives and their community, attracts the next generation of physicians and scientists from within its region, as well as from across Pennsylvania and the nation. In addition to the MD program, Geisinger Commonwealth offers a master's degree in biomedical sciences in both Scranton and Doylestown. The school also has more than 440 trainees in 24 graduate medical education programs and offers 19 accredited fellowships from addiction medicine to vascular surgery. Geisinger Commonwealth is committed to non-discrimination in all employment and educational opportunities.

Hepatitis B Foundation

Global education & advocacy for those affected by Hepatitis B virus

CEO: Tim Block, Ph.D.
tim.block@bblumberg.org
215-489-4900
Hepb.org

The Hepatitis B Foundation is the only national nonprofit organization solely dedicated to finding a cure and improving the quality of life for those affected with hepatitis B worldwide. It provides comprehensive outreach and education programs that touch thousands of lives each year and funds research conducted in its research institute, the Baruch S. Blumberg Institute (BSBI).

PIE (Philadelphia International Education)

CEO: Wei Xie, Ph.D.
usa-pie.com
wei_xie@merck.com

The Baruch S. Blumberg Institute partners with the Philadelphia International Education (PIE) to provide a six-week summer program aimed to inspire Chinese high school students to expand their horizons by studying science in our world-class hepatitis B research facility in the United States. This rigorous High School Science Research Program is open to talented high school students, age 16-19, interested in learning about research, biotechnology, and public health in the context of hepatitis B and liver cancer.

BIOTECHNOLOGY

Advanced Neural Dynamics

Compounds for neurological disease

Douglas Brenneman, Ph.D., CEO
advneuraldynamics.com
dbrenneman@advnerualdynamics.com
(215) 822-6359

Advanced Neural Dynamics is a drug discovery company focused on preclinical advancement of novel compounds for the treatment of neurological disease. The specialty of the company is neuroprotection from agents that are involved in the causes of neurological impairment.

Advent Therapeutics

Developing therapies for micro-orphan applications.

David Lopez, Ph.D., CEO
David.lopez@Advent-Therapeutics.com

Advent Therapeutics was formed by senior industry executives with extensive expertise and proven track records in Neonatal / Pediatric and similar Orphan Drug “niche” markets to address serious unmet medical needs facing underserved patient populations by taking novel advantage of targeted already commercially-available or late-stage therapeutic opportunities – A Platform Approach to serving the most fragile patients.

Alliance Discovery

Joseph Salvino, Ph.D., CEO
jsalvino@alliancediscovery.com
610-256-6571

For the past 8 years, Alliance Discovery has operated in the Commercial Physical Research business / industry within the Engineering, Accounting, Research, and Management Services sector.

ALS Biopharma

New Small-Molecule Therapeutics for Treatment of ALS and Related Disorders

Allen B. Reitz, Ph.D., CEO
alsbiopharma.com
areitz@alsbiopharma.com
215-589-6435

ALS Biopharma, LLC (ALSBio, www.alsbiopharma.com) was co-founded in 2009 by an angel investor with a personal interest to find new treatments for ALS together with Allen Reitz. The focus of ALSBio, working together with affiliated company Fox Chase Chemical Diversity Center, Inc., remains the discovery of new small-molecule therapies to treat ALS and related disorders.

AniMed Biologics

CEO: Lee Middleberg
animedbiologics.com
215-450-9745

AniMed Biologics was established in 2017 to provide clinically defined material to the veterinary industry.

Antengene Corporation

Multi-source Healthcare Platform through Internal R&D and External Partnership

CEO: Jay Mei, Ph.D.
Jay.mei@antengene.com
antengene.com
267-370-5420

Antengene Corporation is a clinical-stage biopharmaceutical company that focuses on introducing cutting-edge treatments, ranging from early-to-late stage development pipelines to mature brands, to China and other Asian markets. With clinical development and regulatory expertise as well as local market knowledge in Asia Pacific, Antengene collaborates with academic research institutions and leading biotech companies around the world on diseases with higher incidence and urgent needs in China and other Asia Pacific countries/regions.

Arbutus Pharmaceuticals

Dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection.

William Collier, CEO
arbutusbio.com
604-419-3200

Arbutus Biopharma, Inc. is a publicly traded biopharmaceutical company dedicated to discovering, developing and commercializing a cure for patients suffering from chronic hepatitis B infection, a disease of the liver caused by hepatitis B virus (HBV). We are developing a portfolio of drug candidates with multiple mechanisms of action that we believe will result in a combination therapy that will transform the HBV treatment landscape and cure hepatitis B virus disease.

Atrin Pharmaceuticals

Anti-Cancer Drug Discovery

CEO: Oren Gilad, Ph.D.
Oren.gilad@atrinpharma.com
atrinpharma.com
267-370-5219

Atrin Pharmaceuticals is an early stage, emerging biotechnology company focused on developing proprietary medications for the treatment of oncological diseases that currently do not have very effective therapies. Atrin has identified an innovative therapeutic approach that will target major solid cancers including breast, pancreatic, lung, ovarian and colon.

BioPhysical-Solutions

CEO: Matthew Todd, Ph.D.
linkedin.com/in/matthew-todd-a57a0515
matthew.todd@biophysical-solutions.com
215-301-3575

BioPhysical-Solutions encourages wider utilization of biophysical approaches in the Life Sciences. Biophysical techniques often exploit label-free observations to detect molecular interactions (binding) and/or conformational changes. BioPhysical-Solutions offers several unique label-free capabilities: Thermal Stability Analysis for protein formulation or compound binding, and the Corning EPIC technology for both biophysical binding and cell-based assays. It also offer unique permutations of labeled technologies, such as Fluorescence Lifetime analysis using pre-marketed instrumentation from Fluorescence Innovations, Inc.

CaPtivate Pharmaceuticals

Small Biotechnology Company Developing Nanoparticle-based Vaccine/Drug Delivery System

President & CSO: Tulin Morcol, Ph.D.
captivatepharma.com
tmorcol@captivatepharma.com
215-298-3032

CaPtivate calcium phosphate nanoparticle (CaPNP) technology offers a unique platform for delivery of therapeutic drugs, antibiotics against drug-resistant bacteria, or vaccines for systemic or mucosal-local administration. Drugs carried by CaPNPs indicate 100% bioavailability, full functional activity, significantly improved pharmacokinetics and efficacy. Vaccines adsorbed to CaPNPs elicit broad spectrum of enhanced virus-specific immune responses, including high virus neutralizing antibody response, cellular immunity, and high local IgA secretion by mucosal administration. CaPtivate is focused on developing CaPNP as a new adjuvant to improve effectiveness of licensed influenza vaccines in vulnerable populations and enhance national vaccine supplies through dose-sparing in the event of an influenza epidemic/pandemic. CaPtivate actively invites new collaborations, partnerships, and licensing opportunities to utilize CaPNP as a versatile vaccine adjuvant/delivery system for applications in human and animal health.

Diverse Biotech, Inc.

Developer of a biopharmaceutical research platform designed to discover novel therapeutics from cannabinoid products

CBO: Brian Longstreet
blongstreet@diversebiotech.com
diversebiotech.com
908-917-5699

Diverse Biotech, Inc. is an innovative, clinical-stage biopharmaceutical research company that is committed to discovering and developing novel therapeutics from its proprietary and patented cannabinoid formulations and cancer research. The Company's formulas are novel discoveries for improving the health and well-being of cancer patients around the world.

Evrys Life Science, LLC

Early stage concepts in the control of infectious disease.

CEO: Lillian Chiang, Ph.D.
evrys.com
lillian@evrysbio.com
267-893-6755

Evrys Bio was founded on breakthrough discoveries made at Princeton University. Whereas immuno-oncology drugs engage the patient's immune system to fight cancer, Evrys Bio antivirals engage the cell's intrinsic immunity to defend against infection. Evrys Bio's vision is to develop first-in-class antivirals that address the problem of acquired drug-resistance and provide unique broad-spectrum treatment options.

Exios Bio, LLC

Kobby Essien, Ph.D., CEO, Founder
Chwan-Hong Foo, Ph.D., Sr. Scientific Director
exios@exiosbio.com

Exios Bio, LLC accelerates the development of medical countermeasures for infectious diseases by challenging conventional paradigms. These countermeasures include advanced molecular diagnostics for early detection of pathogens, and repurposed antiviral drugs.

Greene Street Pharmaceuticals, LLC

CEO: William Dixon, Esq.
greenestreetpharma.com
Bill@dixonlawyers.com
215-680-5286

Greene Street Pharmaceuticals is a pharmaceutical company that specializes in the formulation and development of abuse deterrent opioid transdermal delivery systems, as well as generic opioid transdermal delivery systems. Green Street directs the formulation and development of transdermal products through a contractual agreement with K&H Pharmaceuticals, LLC.

ImCare Biotech

Diagnostic markers and drugs for detecting Hepatitis and Liver Cancer

Xuanyong Lu, Ph.D., President & CSO
imcarebiotech.com
info@imcarebiotech.com
(215) 489-4906

ImCare Biotech is a start-up biotechnology company to develop innovative technologies in the diagnosis of Hepatitis and Liver Cancer. Currently there is no effective biomarker to detect early occurrence of liver cancer (HCC and ICC) and its recurrence after surgical resection. However, over-expression of serine protease inhibitor Kazal (SPIK) was found in HCC and ICC and the level of SPIK protein in the serum of patients has been demonstrated to correlate with the progress of the cancers.

IO Biosciences

A gene modified therapy company

Sicco Popma, Ph.D., CEO
iobiosciences.com
info@iobiosciences.com
484-680-9357

IO Biosciences is a company focused on developing allogeneic, gene modified cell therapies treating cancers. The company leverages a proprietary gene editing system and cell source, creating a unique opportunity to develop and manufacture of-the-shelf gene modified cell therapies.

Iview Therapeutics

CEO: Bo Liang, Ph.D.
iviewtherapeutics.com
bliang@iviewinc.com
267-370-5223

Iview Therapeutics is a specialty pharmaceutical company focusing on topical drug and medical device development. It focuses on specific therapeutic areas and its development strategy is developing combination product based on existing FDA approved drugs, developing novel drug delivery and slow releasing formulations.

JBS Science

Ying-Hsiu Su, President
JBS-science.com
slin@jbs-science.com
215- 589-6306

JBS Science, Inc. improves cancer management by developing cutting-edge urine DNA-based diagnostic technology for early detection and management of cancer. Its technologies change the way medicine is practiced by detecting primary and recurrent cancers and providing cancer genetics for personalized medicine in a noninvasive urine test.

KannaLife Sciences, Inc.

Cannabinoids as Antioxidants and Neuroprotectants

Dean Petkanas, CEO
kannalife.com
dean@kanalife.com
516-782-6210

KannaLife Sciences, Inc. is a bio-pharmaceutical and phyto-medical company involved in the research and development of novel new therapeutic agents designed to reduce oxidative stress, and act as immuno-modulators and neuroprotectants. KannaLife Sciences currently holds an exclusive license with National Institutes of Health – Office of Technology Transfer for the commercialization of “Cannabinoids as Antioxidants and Neuroprotectants”.

Maria Valentino, LLC

Maria Valentino, CEO
mariavalentino.com
917-439-7415

Maria Valentino is the pioneer of luxury hemp-based cosmetics and therapeutic skincare. Made with only the purest ingredients and scientifically formulated by leading cosmetic experts, Maria Valentino, LLC, produces luxury Botanical Wellness & Beauty products with cutting-edge formulas featuring Full Spectrum CBD, synergy boosting terpenes, Reishi Mushroom, and Active Plant Cells.

Neoventech

topical drug and active cosmetic product development

Jeff Wu, CEO
Neoventech.com
Jwu@neoventech.com
267-261-6611

Drug delivery, transdermal delivery system, cosmetic care and topical drug product development with successful global commercialization.

Mid-Atlantic Bio

immunotherapy for infectious diseases

David Horn, MD, Founder & CEO
mabt.us
info@mabt.us

MABT is a clinical-stage pharmaceutical company focused on the clinical development and commercialization of a novel anti-infective therapeutic approach, which is immunotherapy for infectious diseases. We are actively addressing the growing antibiotic resistance problems and creating a revolutionary treatment paradigm for viral diseases (eg, Tamiflu alternative for influenza), emerging infectious diseases and biodefense.

OKYO Pharma

novel bio-therapeutics in pre-clinical development

Raj Patil, Ph.D., CEO
okyopharma.com
RPatil@okyopharma.com
267-576-6924

OKYO Pharma focuses on diseases of high unmet need, where large market potential exists for effective therapeutics. Its goal is to develop first-in-class drug candidates that prevent disease. OKYO Pharma’s approach is to use the scientific knowledge that is based on molecular pathways involved in disease pathogenesis and target the key fundamental mechanisms, which are the root cause of the disease progression.

Qrumpharma

Thomas Hoffman, MD, PhD, CEO
qrumpharma.com
info@qrumpharma.com
215-345-4150

Pulmonary diseases are on the rise, and mean a substantial burden on patients, caregivers, and society. Specific unmet needs are still present in the areas of Cystic Fibrosis, Asthma and COPD. Qrumpharma is driven by helping those patients and society by using good science that leads to good clinical development. It is Qrumpharma's goal to improve people's lives with intelligent and ethical application of clinical science.

Rasna Therapeutics

Kunwar Shailubhai, Ph.D., CSO
rasna.com
info@rasna.com
215 589-6300

Rasna Therapeutics was formed in 2013 by a highly experienced industry team together with field-leading scientists, to focus on developing therapeutics to address the high unmet need that exists for AML and other forms of leukemia. Its primary indication is acute myeloid leukemia (AML) which may be fatal within weeks to months, has a 5-year survival rate of only about 25% and very poor prospects for long-term survival of patients. Rasna's clinical program is based around three druggable intervention points with potential to improve safety and efficacy of current AML combination therapies.

Sequor BioPharma

Frank Jones, Ph.D., CEO
sequorpharma.com
267-261-6326

Experts in liver disease drug discovery with two products: HCC Liver Cancer and LDL lowering compounds. Both products are advanced through early stage development. Sequor's objective is to continue product(s) development through external partners. HCC Liver cancer product is a new first in class non Kinase product with initial ex vivo results exceeding the 11%-18% response rate for current therapies. LDL product is also a new first in class non- stain product that reduces LDL by 30-40%. Sequor seeks company sponsors to license or sell the products.

Seneca Therapeutics, Inc.

Paul Hallenbeck, Ph.D., CEO
senecatherapeutics.com
phallenbeck@senecatherapeutics.com

STI is developing Seneca Valley Virus (SVV), a novel clinically tested oncolytic virus, for the treatment of cancer. SVV and/or derivatives of SVV will be the first oncolytic immunotherapeutic to specifically target the tumor microenvironment (TME), known for its key role in causing cancer invasion, metastases, and resistance to a wide variety of therapeutics, including immunotherapy. SVV as a monotherapy or in combination with synergistic cmpds (e.g. HDACi, Checkpoint inhibitors) is expected to ablate key cells in the TME and malignant cells and elicit a short-long term anti-cancer immune response leading to patient benefit.

Serologix

Maria Middleberg, Ph.D., CEO
serologix.net
mmiddleberg@serologix.net
215-450-9365

Serologix was established in 2012 and provides clinically defined human material for the biotech and pharma research and development of diagnostic products.

Tiziana Life Sciences

Kunwar Shailunhai, Ph.D., CEO, CSO
tizianalifesciences.com
info@tizianalifesciences.com
215-589-6300

Tiziana Life Sciences' mission is to design and deliver next gen therapeutics and diagnostics for oncology and immune diseases of high unmet need by combining deep understanding of disease biology with clinical developmental expertise. The business employs a lean and virtual R&D business model using highly experienced teams of experts for each business function to maximize value accretion and focus capital on the drug development and discovery processes.

VIAS Partners, LLC

Sanjay Batra, Ph.D., CEO
viaspartners.com
info@viaspartners.com
215-862-5345

VIAS Partners, LLC, is engaged in the research, development and commercialization of autologous, point-of-care systems in regenerative medicine. Its primary focus is to identify and optimize various technologies for the preparation of platelet-rich plasma (PRP) from a small sample of blood. VIAS Partners have recently in-licensed a patent portfolio from GE Healthcare, and are working to understand the role of platelet-derived growth factors across a variety of clinical applications.

MEDICINAL CHEMISTRY TECHNOLOGIES

Conifer Point Pharmaceuticals

John Kulp, Ph.D., CEO
coniferpoint.com
john.kulp@coniferpoint.com
215-589-6357

Conifer Point is an early stage drug discovery company focused on creating successful drug candidates by combining experimental and computational fragment-based techniques. It also offers industry-standard computational chemistry services, at an affordable price, to small companies so they may screen— or synthesize—fewer, more targeted compounds to get reliable, well behaves, and successful hits. Furthermore, Conifer Point's technology, and discovery process, helps generate non-obvious ideas for compound progression.

Fox Chase Chemical Diversity Center, Inc.

Translating scientific discoveries into commercial opportunities

Allen B. Reitz, Ph.D., CEO
fc-cdci.com
areitz@fc-cdci.com
215-589-6416

Fox Chase Chemical Diversity Center, Inc. (FCCDC) is an emerging biotechnology company with a staff of ~28, located at the PA Biotech Center and in laboratories in King of Prussia, PA. FCCDC conducts research to identify new small-molecule therapeutics to treat human disease, often in partnership with academic and non-profit investigators elsewhere. FCCDC has prepared >11,000 New Chemical Entities since its inception in 2008, all in the context of different SAR development campaigns for different indications. FCCDC is a major recipient of small business funding from the National Institutes of Health seeking to advance new therapies into further development for multiple and various indications in neurology, oncology, cardiovascular and infectious disease.

IteraMed, Inc

President: William Kinney, Ph.D.
iteramed.com
wkinney@iteramed.com
215-630-5433

IteraMed provides custom organic synthesis, medicinal chemistry consulting, drug discovery, and manufacturing expertise. IteraMed draws from a number of consultants as needed.

Lam Drug Discovery

Medicinal chemistry and drug discovery consulting and synthesis

Patrick Lam, Ph.D., CEO
blumberginstitute.org/patrick-s-lam/
linkedin.com/in/patrick-lam-3158946
Patrick.y.s.lam@gmail.com
302-547-5129

Lam Drug Discovery Consulting, LLC provides medicinal chemistry and drug discovery expertise. Proven track record of a group leader and co-inventor of a marketed anticoagulant, Eliquis®/apixaban with multi-billion dollar annual sales; and co-discoverer of the powerful Chan-Lam coupling reaction, complimentary to Nobel prize Suzuki-Miyarau coupling reaction.

PharmaGreen

pharmagreen.com
info@pharmagreen.com
(+202) 230 85 497

PharmaGreen is a private company engaged in the pharmaceutical business through registration of its own products for marketing. Since its founding in late 1997, it has introduced a number of evidence-based herbal medicine and pharmaceutical products that address specific health problems.

Epidarus Therapeutics

Deirdre O'Sullivan, Ph.D., Founder & CSO
<https://www.linkedin.com/in/deirdre-o-sullivan-a0809648/>

Epidarus is a start-up company which aims to develop products that modify Hyaluronic Acid metabolism in skin and joints utilizing natural products from the NPDI collection.

CONTRACT RESEARCH ORGANIZATIONS (CROs)

Allturna

Data and analytics

Jim Neumann, Founder & President
Allturna.com
Insights@allturna.com
267-870-8000

Allturna uses data and analytics to connect brands to their customers. Allturna offers strategic thought leadership on CRM coupled with the proven ability to deliver the technology and analytics to bring the strategy to market.

ArVin TaH, Ltd.

Nikil Heble, Esq., President
Nikil.heble@gmail.com
215-735-9302

ArVinTaH Ltd. provides strategic business and legal counsel to a diverse client base, including, e.g., pharmaceutical and consumer product companies; investment firms; emerging growth companies and universities, on a wide variety of intellectual property related matters.

Diagnosearch Life Sciences

Contact: Jennifer Gidley
diagnosearch.com
jgidley@gmail.com

Diagnosearch Life Sciences' mission is to deliver superior research management solutions through a focus on quality, priority customer service and support based on "best science of the day" processes and thus, be a valuable partner of its customers in Clinical Research Management. DiagnoSearch Life Sciences is one of the most experienced full-service CROs in India. Since its inception in 1995, DiagnoSearch has built a substantial track record of supporting hundreds of global clinical development programs across a broad therapeutic spectrum.

FlowMetric Life Sciences, Inc.

Polychromatic Flow Cytometry and
ImmunoHistoChemistry

Contact: Renold Capocasale, Ph.D.
flowcytometryservices.com
(267) 893-6630

FlowMetric Life Sciences, Inc., is a leading provider of flow cytometry and cell sorting services. We serve partners in multiple fields including biotechnology, small and large cap pharmaceuticals, hospitals and academic institutions. Established in 2010, FlowMetric provides state-of-the-art flow cytometry techniques that combine proprietary assays with advanced analytics to support all stages of drug development including pre-clinical, non-clinical and clinical development. FlowMetric offers integrated, cost-effective, and specialized service delivered with an uncompromising commitment to quality.

Pharmabridge Inc.

sales@pharmabridgegroup.com
215-589-6409

Pharmabridge Inc. provides contract research and development activities for pharmaceutical, biotechnology and agricultural industries. With expertise in multi-step synthesis and heterocyclic chemistry, we are committed to provide high quality services to our clients in a timely and cost-effective manner. Its services range from drug discovery services, process research & development, custom synthesis and catalog chemicals. Pharmabridge has the capacity and know-how to handle each step of synthesis in-house.

Sulagen, LLC

Provides drug discovery and development consulting services on antibiotics, antifungal, medicinal chemistry, natural products, fermentation, complex purification, structure elucidation, management of external partner and CRO collaboration, Mycobacterial tuberculosis, and neglected diseases and virtual drug discovery.

The Bracken Group

consultative support for the development of
products

Jim Gilligan, CEO
Thebrackengroup.com
215 648-1208

The Bracken Group (TBG) provides life sciences consulting to pharma, biotech and the companies that serve them. Services include scientific insights, regulatory affairs, medical imaging expertise, business development assistance as well as process development and strategic development in an integrated manner and/or stand-alone project to support programs or studies.

MEDICAL DEVICE TECHNOLOGIES**Advanced Vertebral Solutions**

Vertebral Implants

Contact: Mike Dugery
linkedin.com/in/mikedugery/
mdugery@vasculabtech.com
610-507-8255

Advanced Vertebral Solutions is developing and commercializing a unique “active steering” technology platform for spinal surgery that is comprised of proprietary implants and delivery instruments designed for minimally invasive spine surgery.

N-Zyme Scientifics, LLC

Develop and supply high-performance enzymes in the pharmaceutical, diagnostics, and drug discovery of biologics.

E-mail: sales@n-zymesci.com
n-zymesci.com
267-218-1098

N-Zyme Scientifics, LLC is focused on becoming a transformative force to take Glycobiology-based technologies from its infancy towards a fully-integrated mainstream platform to the benefit the human condition.

OrthoMend Research, Inc.

Fixing Bones and Live

Joseph P. Connell, CEO
Bruce D. Mullen COO
www.orthomend.com
jpconnell@orthomend.com
910-233-0806

OrthoMend Research, Inc. is an emerging Regenerative Orthopedic device company pioneering new technologies intended to revolutionize bone fixation after orthopedic, surgical and trauma situations. OrthoMend Research, Inc. is involved with commercializing technologies licensed from Temple University for an absorbable suite of bone fixation and drug delivery devices. We will develop, test and launch absorbable screws, pins and possibly plates to repair the millions of broken bones occurring each year. We are steadfast to be the leader in orthopedic devices delivering real-world technologies to impact the lives of those in need.

Single Use Surgical

Contact: Carmen Beavis
Carmen.beavis@pelicanhealthcare.uk

Single Use Surgical company is founded on innovation. It strives to continually develop single use instruments that provide customers with a genuine solution to their medical device needs.

NANOTECHNOLOGY

ImmProNano

ImmProNano: advanced expertise providing targeted solutions as an extension of your lab.

Aykan Karabudak-Project and Operations Manager
www.immpronano.com
akarabudak@immpronano.com
215-589-6374

ImmProNano is a preclinical, research and development service provider with expertise in immunology and proteomics. These specialties allow ImmProNano to bring an array of services and capabilities to provide decision enabling results.

NeuEsse Inc.

Joseph P. Connell CEO
neuesse.com
jpconnell@neuesse.com
910-233-0806

NeuEsse Inc. is an emerging regenerative medicine development company with a goal of enhancing the quality of life of consumers and patients by providing novel nano-materials for the repair and regeneration of diseased, traumatized and aging skin. Its innovative technologies are intended to revolutionize the unmet needs in multiple commercial and therapeutic applications in the Regenerative Medicine space.

FACILITIES SUPPORT

Tescor, Inc.

On-site walk-in Freezer Facility

Contact: Jennifer Aughey/Brian Wurtz
tescor-inc.com
jaughey@tescor-inc.com
bwurtz@tescor-inc.com
215-957-9112

Tescor is the world leader in Climatic Testing Equipment for the Automotive, HVAC, Pharmaceutical and Life Sciences industries. Tescor custom-engineered systems enable R&D or QC Labs to test their products in conformance with the appropriate ASHRAE, ARI, AHAM, RAC, IEC or JIS, and ISO standards. Tescor has commissioned several hundred projects to date in the area of calorimetry and environmental test facilities. These projects have been completed for many large, world-leading Automotive, HVAC and Pharmaceutical companies, both domestic and international.

WorldWide Life Sciences, Inc.

Contact: Caitlin Capestro
wwmponline.com
ccaestro@wwmponline.com
215-990-8820

WorldWide Life Sciences Division, Inc. (WWLS) a technologically advanced, quality-driven provider of essential laboratory wares and services to the scientific community, is dedicated to exceeding the wants and needs of our clients. Our mission is to utilize our unique comprehension and understanding of the research and development market, while maintaining the ability to respond and adapt to clients' needs.

BIOTECHNOLOGY BUSINESS SERVICES

Artemis Solutions

Business Support Services

Contact: Kathy Czupich
artemis-finance.com
kczupich@atremis-finance.com
215-489-4944

Artemis Solutions was formed to provide grant support and financial management services to early stage technology-based companies. Artemis Solutions specializes in the application, submission and administration of SBIR grants to early stage technology-based companies. Artemis has a proven record in obtaining government funding for its clients.

Assist Panacea, LLC

Contact: Jim Lenhard
linkedin.com/in/james-lenhard-74b67431
jimalenhard@gmail.com

Assist Panacea, LLC provides consulting services to scientific teams, ranging from drug target and biomarker identification, validation and selection as well as lead identification and optimization, IND-enabling studies, and clinical research. In addition, services include conducting due diligence to evaluate in-licensing and out-licensing opportunities and provide recommendations on research strategies and project prioritization related to pharmaceutical research and development.

Brian Eves, ESQ

Brian Eves, Esq., Principal
brianeveslaw@gmail.com

Attorney Brian Eves' practice is centered upon relationships with his clients. Attorney Eves has a wide range of experience in law enforcement, social services, and employment relations. Representing clients throughout Pennsylvania including Bucks, Carbon, Lehigh, Monroe, Montgomery, and Northampton Counties.

Channel Methods Partners LLC

Brian Feehan
Managing Partner, Chief of Operations

Contact: Nicholas Crane
channelmethods.com
nicholasc@channelmethods.com
877- 353-4399

Channel Methods Partners is an extension of your scientific business development expertise – integrated with your team to provide you the results you deserve. With strategic vision and operational deployment, we can work with you in a variety of pivotal roles and grow you a pipeline of qualified partners for your unique product or service line, across all lifecycles of the Life Sciences Industry. You can benefit from offerings in strategic operations, business development, sales, marketing, branding, negotiation, demand generation and more, to drive your company to desired success.

DarkMatter2bd

Delivering Modern Data Driven Insights for
Healthcare and Life-Sciences

Vince DeChellis, Co-Founder & Principal
darkmatter2bd.com
vince.dechellis@darkmatter2bd.com
215-862-6007

Our team of industry veterans believe that data is the DarkMatter of Healthcare. We look to collaborate with you, our client, to successfully solve complex clinical and business challenges. By leveraging modern technologies and MedFuse data we help you optimize clinical and marketing programs while reducing costs and accelerating results. MedFuse Data is deployed on Qlik, a leading provider of modern data visualization tools. No IT personnel required; MedFuse is business user friendly. In just a short time you will be up and running on MedFuse discovering things you did not know you did not know.

Doylestown Translation Services

dtowntranslation.com
215-230-9600

Doylestown Translation Services is a professional translation company located in Doylestown, PA. We provide multilingual language solutions for your business in a global market including professional translation, proofreading and editing, voice-over recordings, desktop publishing, localization, interpreting and language consultations. We specialize in clinical trials as well as, pharmaceutical and medical translations, but we serve our clients in all other fields of expertise.

GTS Recruiting

Contact: Robert Hoyle, CEO
gtscareers.com
rhoyle@gtscareers.com
267-249-2429

GTS Recruiting is a niche recruiting company specializing in scientific, engineering and clinical placements. Our team supports Life Sciences skillsets for the biotech, pharmaceutical, and medical device industries. Our quality driven recruiting process allows us to identify the ideal candidates for your team, from mid-level employees to senior executives. Our recruiting experts identify and build relationships with the most qualified candidates in the marketplace today. These strong industry relationships allow us to react quickly to your hiring needs.

Hatch Biofund Management

Contact: Vlad Walko, CEO, Fund Manager
Hatchbiofund.com
vwalko@hatchbiofund.com
610-716-1776

Hatch BioFund is an early stage life sciences venture fund formed as a companion fund to the Pennsylvania Biotechnology Center (PABC). With a target of \$50M in funding, Hatch will provide both seed stage and Series A funding to promising companies from its new BioAccelerator and the PABC incubator, as well as other opportunities sourced through its extensive network. Beyond investment resources, Hatch BioFund companies benefit from access to space, shared resources and unique opportunities for

collaboration that support growth and success. Entrepreneurs benefit from easily accessible services from leading experts in business formation, growth and management, selected for their knowledge and success in life sciences.

Life Sciences Workforce and Economic Development Institute

Contact: Robert Bowman, CEO
Bowman5324@gmail.com
215-862-5324

Research, Development and Consulting activities for Life Sciences.

Power 4 LLC

Product portfolio of power protection equipment

Contact: Jim Ference, CEO
Power4llc.com
Jim.ference@power4llc.com
267-614-4847

Today's healthcare environment relies on efficiency and performance. When your facility relies on a clean, uninterrupted power source for success, power protection is critical. When your systems are not performing optimally, quality and reliability is compromised. These inefficiencies directly interfere with patient care leading to inaccurate diagnoses, compromised results, quality of treatment, and your bottom line. Power4 implements clean power strategies that result in more accurate and complete results for better patient diagnosis and a better total overall experience.

ProBioPharm

Jim Self, President
jwself@probiopharm.com
probiopharm.com

ProBioPharm specializes in providing strategy, business development, and commercialization expertise to the biotechnology, pharmaceutical, and vaccine industry. ProBioPharm can assist with business plan and strategy development, fundraising, and all corporate partnering initiatives. With over 30 years in the pharmaceutical industry executing deals around the world, ProBioPharm's passion is helping you get your deal done.

Premier Focus Solutions

Flexible, Creative, No-Minimum Staffing Solutions for an Evolving Life Sciences Marketplace

Kyle Fenstermaker, President
www.premierfocussolutions.com
kyle@premierfocussolutions.com
267-614-1734

"Premier Focus Solutions cultivates a network of life sciences experts at every level (from former VPs to individual contributors). We offer these folks to our clients through a flexible model with no retainer or minimum commitment. Whether you need one specific skillset for 10 hours or a cross functional team of consultants we can help!

VeriSIM Life

Using AI simulations powered by machine learning intelligence systems for healthcare development

Jo Varshney, Founder & CEO
www2.verisimlife.com
info@verisimlife.com
415-991-3783

The cost and time of developing new medications have been growing for decades. Modeling and simulation approaches have potential to reduce the time and cost and restore sustainability to drug development. VeriSIM Life is on the leading edge of this next phase of drug development using AI and machine learning to more efficiently and effectively predict pharmacology of potential new drug candidates through pharmacokinetic and pharmacodynamic modeling and simulation.

StraNexa BioPharm Commercialization Consultancy, LLC

We have a passion for helping our clients unlock the promise of the science and commercialize new standards of care that improve patient outcomes, whether through their own or partnered assets.

Contact: Leo Adalbert, CEO
stranexa.com
leo.adalbert@stranexa.com
610-505-3891

StraNexa LLC provides insight-driven commercialization expertise to the biopharmaceutical industry to create and sustain competitive advantage. We are committed to help our clients achieve commercialization excellence and breakthrough business results. In partnering with both for-profit and non-profit firms, we help clients extend their reach and impact to enhance financial performance and improve the lives and patients and communities.